Experiences of Clinical Practice-Based Treatment with a 3-Month Dosage Form of Leuprorelin
Leuprorelin 3-month depot is as effective as other treatments for CPP and may improve compliance due to reduced injection frequency.
Where it sits
this study against the rest of the goserelin corpusSummary and findings
This study retrospectively analyzed 60 children with progressive idiopathic CPP or precocious puberty, comparing leuprorelin 3-month depot, triptorelin 1-month depot, and combination therapy over 24 months. No statistically significant differences were found in sex hormone levels, growth rate, maturity, or bone age growth rate among the groups. The leuprorelin 3-month depot was found to be cost-effective and improved patient compliance.
Abstract
<h4>Objectives: </h4> Despite the widespread use of the leuprorelin 3-month depot in central precocious puberty (CPP), its clinical efficacy and patient follow-up remain unexplored. This study aimed to compare the clinical indicators of the leuprorelin 3-month depot and triptorelin 1-month depot following treatment in a CPP cohort to understand the therapeutic effect of the former. <h4>Methods:</h4> A retrospective analysis was performed on 60 children diagnosed with progressive idiopathic CPP or precocious puberty who received at least 24 months of treatment at the hospital. The treatment involved leuprorelin 3-month depot for 18 participants, triptorelin 1-month depot for 16 participants, and a combination of both drugs for 26 participants. Anthropometric, biochemical, and bone age (BA) data were examined before treatment and every 12 months during treatment. <h4>Results:</h4> Before treatment, no statistical differences were noted in the baseline levels of sex hormones (oestradiol (E2), luteinising hormone (LH), and follicle-stimulating hormone (FSH)) among the triptorelin 1-month depot, leuprorelin 3-month depot, and combination therapy groups (P&gt;0.05). However, the serum testosterone levels among participants were statistically significant (P &lt; 0.05). After 1 and 2 years of treatment, no statistically significant differences were noted in the baseline levels of sex hormones (E2, LH, and FSH) among the three groups (P&gt;0.05). At baseline, no statistical differences were found in BA, height, or weight among the groups (P&gt;0.05). After 1 and 2 years of treatment, no statistically significant differences were observed in the growth rate, maturity, or BA growth rate of the participants in all three groups (P&gt;0.05). <h4>Conclusions:</h4> The therapeutic effects of the triptorelin 1-month and leuprorelin 3-month depots were equivalent. Furthermore, treatment with leuprorelin 3-month depot is cost-effective compared with the other options . It reduces the number of injections administered to paediatric patients, the time spent on medical visits, and improves compliance, leading to greater acceptance among patients.
Background
The study addresses the clinical efficacy and follow-up of leuprorelin 3-month depot in treating central precocious puberty (CPP), a condition where puberty starts too early in children. While leuprorelin is widely used, its comparative effectiveness with other treatments like triptorelin has not been thoroughly explored. Understanding these differences is important for optimizing treatment strategies and improving patient outcomes.
Methods
A retrospective analysis was conducted on 60 children diagnosed with progressive idiopathic CPP or precocious puberty. Participants received at least 24 months of treatment with either leuprorelin 3-month depot, triptorelin 1-month depot, or a combination of both. Anthropometric, biochemical, and bone age data were collected before treatment and every 12 months during treatment. The primary outcomes were changes in sex hormone levels, growth rate, and bone age growth rate.
Results
The study found no statistically significant differences in baseline sex hormone levels (oestradiol, luteinising hormone, and follicle-stimulating hormone) or in growth metrics such as height, weight, and bone age among the treatment groups (P>0.05). Serum testosterone levels showed statistical significance at baseline (P<0.05), but no significant differences were observed in hormone levels or growth metrics after 1 and 2 years of treatment.
Interpretation
The findings suggest that the leuprorelin 3-month depot is as effective as the triptorelin 1-month depot and combination therapy in managing CPP, with no significant differences in hormone levels or growth outcomes. The study's retrospective design and small sample size limit the strength of these conclusions. However, the leuprorelin 3-month depot may offer practical advantages such as cost-effectiveness and improved compliance, which could be beneficial in clinical practice.
Key findings
- n=60 children with CPP or precocious puberty
- 18 received leuprorelin 3-month depot
- 16 received triptorelin 1-month depot
- 26 received combination therapy
- No significant differences in sex hormone levels (P>0.05)
- No significant differences in growth or bone age (P>0.05)
Limitations
- retrospective design
- small sample size (n=60)
- potential selection bias
- single-site study
- short follow-up for long-term outcomes